Tango Therapeutics, Inc. (TNGX) Investor Relations Documents

Tango Therapeutics, Inc. (TNGX) investor relations documents from the company's IR site: 2 presentations, 19 press releases; latest deck 2026-06-23. Read in-app with summaries. First-party data.

Tango Therapeutics Corporate Presentation: Tango Therapeutics June 2026 investor update highlights a $380M cash position and clinical progress for its PRMT5 inhibitor franchise in MTAP-deleted cancers.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-11	Press release	Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-06	Press release	Tango Therapeutics Announces Executive Chair Transition
2026-06-23	Presentation	Tango Therapeutics Corporate Presentation
2026-06-22	Press release	Tango Therapeutics Appoints Robert Azelby to Board of Directors
2026-06-09	Press release	Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
2026-06-08	Presentation	View Presentation
2026-06-08	Press release	Tango Therapeutics Announces Proposed $500 Million Public Offering
2026-06-08	Press release	Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pa
2026-06-05	Press release	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-13	Press release	Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
2026-05-04	Press release	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-15	Press release	Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
2026-03-06	Press release	Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
	Press release	Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
2026-02-03	Press release	Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-08	Press release	Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
2026-01-05	Press release	Tango Therapeutics Appoints Sung Lee to Board of Directors
	Press release	Tango Therapeutics Raises $60 Million Series B Financing and Strengthens Executive Team
	Press release	Tango Therapeutics Announces $50 Million Equity Financing
	Press release	Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Com
	Press release	Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

TNGX overview · TNGX earnings · TNGX financials · TNGX KPIs · TNGX documents · TNGX ownership · TNGX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.